MAIA Biotechnology Announces Private Placement Agreement

MAIA Biotechnology, Inc. ( (MAIA) ) has provided an announcement.

On May 27, 2025, MAIA Biotechnology, Inc. announced a private placement agreement with accredited investors and a company director for the sale of 463,332 shares of common stock, along with warrants to purchase additional shares, totaling approximately $695,000. The proceeds will fund the Phase II trial THIO-101 and working capital, with the closing expected by May 29, 2025.

The most recent analyst rating on (MAIA) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on MAIA Biotechnology, Inc. stock, see the MAIA Stock Forecast page.

Spark’s Take on MAIA Stock

According to Spark, TipRanks’ AI Analyst, MAIA is a Neutral.

MAIA Biotechnology presents a mixed outlook. The company’s financial performance is weak due to its development-stage status and lack of revenue, contributing to a low financial performance score. However, recent positive trial results and technical indicators showing short-term upward momentum provide a more optimistic view. Valuation remains challenging due to negative earnings, but the potential for significant clinical advancements offers upside potential.

To see Spark’s full report on MAIA stock, click here.

More about MAIA Biotechnology, Inc.

MAIA Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on developing targeted immunotherapies for cancer. The company is working on potential first-in-class drugs with novel mechanisms of action, aiming to improve and extend the lives of cancer patients. Its lead program involves ateganosine (THIO), a cancer telomere targeting agent for treating NSCLC patients with telomerase-positive cancer cells.

Average Trading Volume: 206,347

Technical Sentiment Signal: Sell

Current Market Cap: $53.95M

See more insights into MAIA stock on TipRanks’ Stock Analysis page.